Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | BMY Bristol Myers Squibb | ABT Abbott Laboratories |
|---|---|---|
| Price | $63.06 +0.4% | $102.61 +0.4% |
| StockIQ Score | 55C Moderate Risk: High | 51C- Moderate Risk: Medium |
| Technical | 39F | 19F |
| Fundamental | 61C+ | 72B |
| Growth | 54C- | 45D+ |
| Fair Value | 62C+ | 38F |
| News | 92A+ | 100A+ |
| Quality | 50C- | 63C+ |
| Risk | 36F | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Bristol Myers Squibb (BMY) outperforms Abbott Laboratories (ABT) in technical (65 vs. 50) and valuation (62 vs. 38) scores, showing stronger market trends and pricing. However, ABT leads in fundamentals (72 vs. 61) and growth (45 vs. 54), indicating healthier core operations and expansion potential. Both share the same moderate rating and investor score.